Atrial fibrillation screening on systematic ambulatory electrocardiogram monitoring after percutaneous patent foramen ovale closure: A prospective study

Background: Increased risk of new-onset atrial fibrillation (AF) after patent foramen ovale (PFO) closure was observed in randomized trials without however systematic AF screening. We aimed to evaluate the incidence of AF within 6-month following PFO closure with serial 24-hour ambulatory electrocar...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Florence Leclercq, Xavier Odorico, Gregory Marin, Jean Christophe Macia, Delphine Delseny, Audrey Agullo, Laurence Pages, Pierre Robert, Benoit Lattuca, Guillaume Cayla, François Roubille, Nicolas Gaillard, Caroline Arquizan, Mariama Akodad
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://doaj.org/article/caacee63836941cdb5f9a2b5f281adf0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:caacee63836941cdb5f9a2b5f281adf0
record_format dspace
spelling oai:doaj.org-article:caacee63836941cdb5f9a2b5f281adf02021-11-22T04:27:19ZAtrial fibrillation screening on systematic ambulatory electrocardiogram monitoring after percutaneous patent foramen ovale closure: A prospective study2352-906710.1016/j.ijcha.2021.100919https://doaj.org/article/caacee63836941cdb5f9a2b5f281adf02021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2352906721002074https://doaj.org/toc/2352-9067Background: Increased risk of new-onset atrial fibrillation (AF) after patent foramen ovale (PFO) closure was observed in randomized trials without however systematic AF screening. We aimed to evaluate the incidence of AF within 6-month following PFO closure with serial 24-hour ambulatory electrocardiogram (AECG) monitoring. Methods: All patients undergoing PFO closure were prospectively included in 2 centers. AF was defined as irregular rhythm without discernible P waves > 30 s on AECG at day 0, 1-month and 6-month follow-up. Primary endpoint was the incidence of AF within the study period. Secondary endpoints evaluated clinical outcomes within 6-month follow-up. Results: Between February 2018 and March 2019, 62 patients underwent PFO closure including 40 male (64.5%) with a mean age of 48 ± 9.5. Atrial septal aneurysm was observed in 37 patients (64.9%), 57 patients (91.9%) received an Amplatzer Occluder device (Abbott Vascular) and 5 (8.1%) an Occlutech device (Occlutech). After a mean follow-up of 7.7 ± 2.8 months, new-onset AF occurred in 3 patients (4.8%), all within the first month following PFO closure, including one per-procedural, all were asymptomatic and paroxysmal. Two patients with AF (3.2%) required chronic oral anticoagulant therapy. No adverse outcomes occurred at follow-up. No predictive factors of AF were highlighted. A total of 16 patients (25.8%) reported palpitations without AF on the AECGs. Conclusion: In highly selected patients, incidence of AF, evaluated with 3 systematic 24-hour AECG within 6-month following PFO closure, was low (<5%). Always paroxysmal, AF occurred within the first month after the procedure and was not associated with adverse outcomes.Florence LeclercqXavier OdoricoGregory MarinJean Christophe MaciaDelphine DelsenyAudrey AgulloLaurence PagesPierre RobertBenoit LattucaGuillaume CaylaFrançois RoubilleNicolas GaillardCaroline ArquizanMariama AkodadElsevierarticleAtrial FibrillationHolter MonitoringPatent foramen ovalePercutaneous closureDiseases of the circulatory (Cardiovascular) systemRC666-701ENInternational Journal of Cardiology: Heart & Vasculature, Vol 37, Iss , Pp 100919- (2021)
institution DOAJ
collection DOAJ
language EN
topic Atrial Fibrillation
Holter Monitoring
Patent foramen ovale
Percutaneous closure
Diseases of the circulatory (Cardiovascular) system
RC666-701
spellingShingle Atrial Fibrillation
Holter Monitoring
Patent foramen ovale
Percutaneous closure
Diseases of the circulatory (Cardiovascular) system
RC666-701
Florence Leclercq
Xavier Odorico
Gregory Marin
Jean Christophe Macia
Delphine Delseny
Audrey Agullo
Laurence Pages
Pierre Robert
Benoit Lattuca
Guillaume Cayla
François Roubille
Nicolas Gaillard
Caroline Arquizan
Mariama Akodad
Atrial fibrillation screening on systematic ambulatory electrocardiogram monitoring after percutaneous patent foramen ovale closure: A prospective study
description Background: Increased risk of new-onset atrial fibrillation (AF) after patent foramen ovale (PFO) closure was observed in randomized trials without however systematic AF screening. We aimed to evaluate the incidence of AF within 6-month following PFO closure with serial 24-hour ambulatory electrocardiogram (AECG) monitoring. Methods: All patients undergoing PFO closure were prospectively included in 2 centers. AF was defined as irregular rhythm without discernible P waves > 30 s on AECG at day 0, 1-month and 6-month follow-up. Primary endpoint was the incidence of AF within the study period. Secondary endpoints evaluated clinical outcomes within 6-month follow-up. Results: Between February 2018 and March 2019, 62 patients underwent PFO closure including 40 male (64.5%) with a mean age of 48 ± 9.5. Atrial septal aneurysm was observed in 37 patients (64.9%), 57 patients (91.9%) received an Amplatzer Occluder device (Abbott Vascular) and 5 (8.1%) an Occlutech device (Occlutech). After a mean follow-up of 7.7 ± 2.8 months, new-onset AF occurred in 3 patients (4.8%), all within the first month following PFO closure, including one per-procedural, all were asymptomatic and paroxysmal. Two patients with AF (3.2%) required chronic oral anticoagulant therapy. No adverse outcomes occurred at follow-up. No predictive factors of AF were highlighted. A total of 16 patients (25.8%) reported palpitations without AF on the AECGs. Conclusion: In highly selected patients, incidence of AF, evaluated with 3 systematic 24-hour AECG within 6-month following PFO closure, was low (<5%). Always paroxysmal, AF occurred within the first month after the procedure and was not associated with adverse outcomes.
format article
author Florence Leclercq
Xavier Odorico
Gregory Marin
Jean Christophe Macia
Delphine Delseny
Audrey Agullo
Laurence Pages
Pierre Robert
Benoit Lattuca
Guillaume Cayla
François Roubille
Nicolas Gaillard
Caroline Arquizan
Mariama Akodad
author_facet Florence Leclercq
Xavier Odorico
Gregory Marin
Jean Christophe Macia
Delphine Delseny
Audrey Agullo
Laurence Pages
Pierre Robert
Benoit Lattuca
Guillaume Cayla
François Roubille
Nicolas Gaillard
Caroline Arquizan
Mariama Akodad
author_sort Florence Leclercq
title Atrial fibrillation screening on systematic ambulatory electrocardiogram monitoring after percutaneous patent foramen ovale closure: A prospective study
title_short Atrial fibrillation screening on systematic ambulatory electrocardiogram monitoring after percutaneous patent foramen ovale closure: A prospective study
title_full Atrial fibrillation screening on systematic ambulatory electrocardiogram monitoring after percutaneous patent foramen ovale closure: A prospective study
title_fullStr Atrial fibrillation screening on systematic ambulatory electrocardiogram monitoring after percutaneous patent foramen ovale closure: A prospective study
title_full_unstemmed Atrial fibrillation screening on systematic ambulatory electrocardiogram monitoring after percutaneous patent foramen ovale closure: A prospective study
title_sort atrial fibrillation screening on systematic ambulatory electrocardiogram monitoring after percutaneous patent foramen ovale closure: a prospective study
publisher Elsevier
publishDate 2021
url https://doaj.org/article/caacee63836941cdb5f9a2b5f281adf0
work_keys_str_mv AT florenceleclercq atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT xavierodorico atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT gregorymarin atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT jeanchristophemacia atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT delphinedelseny atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT audreyagullo atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT laurencepages atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT pierrerobert atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT benoitlattuca atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT guillaumecayla atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT francoisroubille atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT nicolasgaillard atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT carolinearquizan atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
AT mariamaakodad atrialfibrillationscreeningonsystematicambulatoryelectrocardiogrammonitoringafterpercutaneouspatentforamenovaleclosureaprospectivestudy
_version_ 1718418186818289664